Moleculin Biotech Inc (MBRX)
2.45
0.00 (0.00%)
USD |
NASDAQ |
Nov 04, 16:00
2.43
-0.02
(-0.82%)
After-Hours: 20:00
Moleculin Biotech Net Income (Quarterly): -4.319M for June 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | -4.319M |
March 31, 2024 | -4.97M |
December 31, 2023 | -10.27M |
September 30, 2023 | -5.609M |
June 30, 2023 | -5.976M |
March 31, 2023 | -7.915M |
December 31, 2022 | -6.77M |
September 30, 2022 | -8.611M |
June 30, 2022 | -6.777M |
March 31, 2022 | -6.867M |
December 31, 2021 | -2.825M |
September 30, 2021 | -4.379M |
June 30, 2021 | -4.244M |
March 31, 2021 | -4.445M |
December 31, 2020 | -2.639M |
September 30, 2020 | -3.395M |
June 30, 2020 | -10.11M |
Date | Value |
---|---|
March 31, 2020 | -1.209M |
December 31, 2019 | -3.797M |
September 30, 2019 | -4.145M |
June 30, 2019 | -1.221M |
March 31, 2019 | -4.041M |
December 31, 2018 | -2.785M |
September 30, 2018 | -2.038M |
June 30, 2018 | -5.125M |
March 31, 2018 | -1.927M |
December 31, 2017 | -3.185M |
September 30, 2017 | -2.866M |
June 30, 2017 | -3.424M |
March 31, 2017 | -0.329M |
December 31, 2016 | -1.423M |
September 30, 2016 | -1.432M |
June 30, 2016 | -0.739M |
March 31, 2016 | -0.332M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-10.27M
Minimum
Dec 2023
-1.209M
Maximum
Mar 2020
-5.533M
Average
-4.97M
Median
Mar 2024
Net Income (Quarterly) Benchmarks
Agilent Technologies Inc | 282.00M |
Seelos Therapeutics Inc | 1.71M |
Cara Therapeutics Inc | -20.02M |
Citius Pharmaceuticals Inc | -10.57M |
NovaBay Pharmaceuticals Inc | -1.585M |
Net Income (Quarterly) Related Metrics
Total Expenses (Quarterly) | 6.185M |
EPS Diluted (Quarterly) | -1.70 |
Enterprise Value | -3.876M |
Earnings Yield | -486.2% |